Daxxify™ (daxibotulinumtoxinA-lanm) – New drug approval
September 8, 2022 - Revance Therapeutics announced the FDA approval of Daxxify (daxibotulinumtoxinA-lanm), for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.
Top